Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
| Status: | Completed |
|---|---|
| Conditions: | Skin Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/14/2018 |
| Start Date: | April 2010 |
| End Date: | February 2012 |
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas
Basal cell carcinomas (BCCs) are the most common human cancer in the US and affect over 1
million people. There is no effective drug to prevent basal cell carcinomas of the skin.
We hope to learn if an oral anti-fungal drug, itraconazole, might inhibit a marker of
proliferation and a biomarker (tumor signaling pathway) of BCC development.
Itraconazole is an FDA-approved drug for the treatment of fungal infections of the skin, and
has been used for the past 25 years with relatively few side effects. It has been shown in
mice to reduce a BCC biomarker and to reduce growth of BCCs.
Thus, it may reduce BCC growth in humans.
million people. There is no effective drug to prevent basal cell carcinomas of the skin.
We hope to learn if an oral anti-fungal drug, itraconazole, might inhibit a marker of
proliferation and a biomarker (tumor signaling pathway) of BCC development.
Itraconazole is an FDA-approved drug for the treatment of fungal infections of the skin, and
has been used for the past 25 years with relatively few side effects. It has been shown in
mice to reduce a BCC biomarker and to reduce growth of BCCs.
Thus, it may reduce BCC growth in humans.
Participants with at least one BCC tumor measuring 4 mm or greater in diameter will be
enrolled onto 1 of 2 treatment cohorts to receive oral itraconazole.
- Cohort A - 400 mg itraconazole (as 200 mg twice daily for 30 days), stratified by:
- Cohort A1 - Participants are vismodegib-naive.
- Cohort A2 - Participants had received prior vismodegib treatment.
- Cohort B - 200 mg itraconazole (as 100 mg twice daily, for up to 4 months). The
objective of this cohort is to assess the anti-cancer efficacy of lower-dose extended
treatment.
- Control Group - Tumors from untreated participants.
enrolled onto 1 of 2 treatment cohorts to receive oral itraconazole.
- Cohort A - 400 mg itraconazole (as 200 mg twice daily for 30 days), stratified by:
- Cohort A1 - Participants are vismodegib-naive.
- Cohort A2 - Participants had received prior vismodegib treatment.
- Cohort B - 200 mg itraconazole (as 100 mg twice daily, for up to 4 months). The
objective of this cohort is to assess the anti-cancer efficacy of lower-dose extended
treatment.
- Control Group - Tumors from untreated participants.
INCLUSION CRITERIA
- At least one BCC tumor (greater than 4 mm in diameter) at any skin location, to be
biopsied and surgically removed.
- Had at least one liver function test [eg, aspartate aminotransferase (AST), alanine
aminotransferase (ALT)] with normal results in the last year.
- Consent to research use of their BCC tissue.
- Cohort A or B: Willing to take itraconazole during the 2 to 3 weeks between biopsy and
surgical removal of BCC
EXCLUSION CRITERIA
- History or current hepatitis or other liver disease.
- Currently taking systemic medications that would affect BCC tumors (oral retinoids) or
metabolism of itraconazole (anti-convulsants, corticosteroids)
- History or current evidence of malabsorption or liver disease within the one year
prior to enrollment.
- History or current evidence of hyperthyroidism increasing metabolism of itraconazole
- Unable to attend to 2nd study visit at Stanford for Mohs surgical excision
- Current immunosuppression disease (cancer, autoimmune disease)
- Receiving immunosuppressive drugs
- Pregnant
- Lactating
- Any female actively trying to become pregnant
We found this trial at
1
site
Stanford University School of Medicine Vast in both its physical scale and its impact on...
Click here to add this to my saved trials
